Why Fennec Pharmaceuticals Inc.’s (FENC) Stock Is Up 5.17%
As of Tuesday, November 17, Fennec Pharmaceuticals Inc.’s FENC share price has surged by 5.17%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Rosalio Madrigal
Tudor Pop
Jenna Brashear
| Share Statistics | FENC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $470.6 | $213.9 | 38% |
|
| Shares Out (Mil) | 38.1 | 55.4 | 41% |
|
| Institutional Ownership | 93.2% | 93.3% | 62% |
|
| Float (Mil) | 24.6 | 40.6 | 32% |
|
| Beta | 1.21 | 0.98 | 71% |
|
| Avg Daily Volume (000s) | 408 | 597 | 54% |
|
| Price Change (52-week) |
52.3% | 40.9% | 87% |
|
| Growth | FENC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 194.9% | 13.2% | 100% |
|
| Net Income (5yr) | 11.7% | (10.7%) | 58% |
|
| EPS (5yr) | 14.9% | 15.5% | 56 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (12.5%) | (15.7%) | 56% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | $0.178 | $0.392 | $1.050 | |
| Month Ago EPS | $0.138 | $0.322 | $0.948 | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 2 | 0 | |
| Three Months Ago EPS | $0.144 | $0.334 | $0.952 | |
| Year/Year Chg | 48.3% | (215.0%) | (636.1%) | |
| Financials | FENC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $66 | $39 | 22% |
|
| Net Income (TTM) (Mil) | $2 | ($44) | 40% |
|
| EPS (TTM) | $0.060 | ($1.400) | 41% |
|
| Operating Cash Flow (TTM) (Mil) | $3 | ($34) | 34% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $362 | $135 | 32% |
|
| Valuation | FENC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.52 | 1.97 | 91% |
|
| P/E | 222.2 | 17.6 | 98% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 14.9 | 0.8 | 96% |
|
| Ratios | FENC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 94.1% | 67.9% | 95% |
|
| Net Margin | 3.1% | (50.8%) | 40% |
|
| ROA | 3.1% | (47.5%) | 61% |
|
| ROE | 9.1% | (51.9%) | 53% |
|
| Liabilities to Assets | 41.1% | 29.7% | 32% |
|
| F-Score | 8 | 3 | 93% |
|
Fennec Pharmaceuticals Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors